PL3077389T3 - KRYSTALICZNA POSTAĆ (S)-(2-(6-CHLORO-7-METYLO-1H-BENZO[D]lMIDAZOL-2-ILO)- 2-METYLOPIROLIDYN-1-YLO)(5-METOKSY-2-(2H-1,2,3-TRIAZOL-2-ILO)FENYLO)METANONU I JEJ ZASTOSOWANIE JAKO ANTAGONISTY RECEPTORA OREKSYNY - Google Patents

KRYSTALICZNA POSTAĆ (S)-(2-(6-CHLORO-7-METYLO-1H-BENZO[D]lMIDAZOL-2-ILO)- 2-METYLOPIROLIDYN-1-YLO)(5-METOKSY-2-(2H-1,2,3-TRIAZOL-2-ILO)FENYLO)METANONU I JEJ ZASTOSOWANIE JAKO ANTAGONISTY RECEPTORA OREKSYNY

Info

Publication number
PL3077389T3
PL3077389T3 PL14824107T PL14824107T PL3077389T3 PL 3077389 T3 PL3077389 T3 PL 3077389T3 PL 14824107 T PL14824107 T PL 14824107T PL 14824107 T PL14824107 T PL 14824107T PL 3077389 T3 PL3077389 T3 PL 3077389T3
Authority
PL
Poland
Prior art keywords
methylpyrrolidin
methanone
triazol
imidazol
benzo
Prior art date
Application number
PL14824107T
Other languages
English (en)
Inventor
Christoph Boss
Christine Brotschi
Markus Gude
Bibia Heidmann
Thierry Sifferlen
Raumer Markus Von
Jodi T. Williams
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of PL3077389T3 publication Critical patent/PL3077389T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41921,2,3-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL14824107T 2013-12-03 2014-12-02 KRYSTALICZNA POSTAĆ (S)-(2-(6-CHLORO-7-METYLO-1H-BENZO[D]lMIDAZOL-2-ILO)- 2-METYLOPIROLIDYN-1-YLO)(5-METOKSY-2-(2H-1,2,3-TRIAZOL-2-ILO)FENYLO)METANONU I JEJ ZASTOSOWANIE JAKO ANTAGONISTY RECEPTORA OREKSYNY PL3077389T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IB2013060596 2013-12-03
EP14824107.8A EP3077389B1 (en) 2013-12-03 2014-12-02 Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists
PCT/IB2014/066508 WO2015083070A1 (en) 2013-12-03 2014-12-02 Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists

Publications (1)

Publication Number Publication Date
PL3077389T3 true PL3077389T3 (pl) 2018-03-30

Family

ID=52282786

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14824107T PL3077389T3 (pl) 2013-12-03 2014-12-02 KRYSTALICZNA POSTAĆ (S)-(2-(6-CHLORO-7-METYLO-1H-BENZO[D]lMIDAZOL-2-ILO)- 2-METYLOPIROLIDYN-1-YLO)(5-METOKSY-2-(2H-1,2,3-TRIAZOL-2-ILO)FENYLO)METANONU I JEJ ZASTOSOWANIE JAKO ANTAGONISTY RECEPTORA OREKSYNY

Country Status (31)

Country Link
US (1) US9914720B2 (pl)
EP (1) EP3077389B1 (pl)
JP (1) JP6496733B2 (pl)
KR (1) KR102361418B1 (pl)
CN (1) CN105793257B (pl)
AU (1) AU2014358742B2 (pl)
CA (1) CA2929423C (pl)
CL (1) CL2016001342A1 (pl)
CY (1) CY1119695T1 (pl)
DK (1) DK3077389T3 (pl)
EA (1) EA030137B1 (pl)
ES (1) ES2651475T3 (pl)
HK (1) HK1225731B (pl)
HR (1) HRP20171773T1 (pl)
HU (1) HUE035731T2 (pl)
IL (1) IL245923B (pl)
LT (1) LT3077389T (pl)
MA (1) MA39163B1 (pl)
MX (1) MX364208B (pl)
MY (1) MY179862A (pl)
NO (1) NO3077389T3 (pl)
NZ (1) NZ721438A (pl)
PH (1) PH12016500988B1 (pl)
PL (1) PL3077389T3 (pl)
PT (1) PT3077389T (pl)
SA (1) SA516371231B1 (pl)
SI (1) SI3077389T1 (pl)
TW (1) TWI664177B (pl)
UA (1) UA119549C2 (pl)
WO (1) WO2015083070A1 (pl)
ZA (1) ZA201604499B (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA029899B1 (ru) 2012-06-04 2018-05-31 Идорсиа Фармасьютиклз Лтд Производные бензимидазол-пролина
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
DK3077391T3 (en) 2013-12-04 2018-10-22 Idorsia Pharmaceuticals Ltd USE OF BENZIMIDAZOLE PROLINE DERIVATIVES
PL3619199T3 (pl) 2017-05-03 2021-12-20 Idorsia Pharmaceuticals Ltd Wytwarzanie pochodnych kwasu 2-([1,2,3]triazol-2-ilo)­-benzoesowego
CA3175369A1 (en) 2020-04-19 2021-10-28 Guy Braunstein Medical use of daridorexant
CN116783182A (zh) * 2021-02-02 2023-09-19 南京明德新药研发有限公司 四氢吡咯并环化合物及其应用
WO2023160004A1 (zh) * 2022-02-25 2023-08-31 南京知和医药科技有限公司 具有镇痛活性的稠环化合物及其制备方法与用途

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3282927A (en) 1964-05-21 1966-11-01 Bristol Myers Co 5-phenyl-4-thiazolylpenicillins
ATE293101T1 (de) 2000-06-16 2005-04-15 Smithkline Beecham Plc Piperidine zur verwendung als orexin rezeptor antagonisten
AU2001296799A1 (en) 2000-10-06 2002-04-15 Neurogen Corporation Benzimidazole and indole derivatives as crf receptor modulators
DE60108420T2 (de) 2000-11-28 2005-12-22 Smithkline Beecham P.L.C., Brentford Morpholinderivate als antagonisten an orexinrezeptoren
AU2002253361B2 (en) 2001-05-05 2006-08-17 Smithkline Beecham P.L.C. N-aroyl cyclic amines
WO2002089800A2 (en) 2001-05-05 2002-11-14 Smithkline Beecham P.L.C. N-aroyl cyclic amine derivatives as orexin receptor antagonists
IL159041A0 (en) * 2001-06-28 2004-05-12 Smithkline Beecham Plc N-aroyl cyclic amine derivatives as orexin receptor antagonists
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
GB0124463D0 (en) 2001-10-11 2001-12-05 Smithkline Beecham Plc Compounds
GB0127145D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Compounds
GB0130335D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
GB0130393D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
AU2003262516A1 (en) 2002-09-18 2004-04-08 Glaxo Group Limited N-aroyl cyclic amines as orexin receptor antagonists
GB0225938D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225884D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225944D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
BRPI0508263B8 (pt) 2004-03-01 2021-05-25 Idorsia Pharmaceuticals Ltd derivados de 1, 2, 3, 4-tetra-hidro-isoquinolina, composição farmacêutica, e, uso de derivado de 1, 2, 3, 4-tetra-hidro-isoquinolina
UA93903C2 (ru) 2006-03-15 2011-03-25 Актелион Фармасьютикалз Лтд Производные тетрагидроизохинолина для повышения функции памяти
WO2007135527A2 (en) * 2006-05-23 2007-11-29 Pfizer Products Inc. Benzimidazolyl compounds
BRPI0715893A2 (pt) 2006-08-15 2013-09-17 Actelion Pharmaceuticals Ltd composto de azetidina e uso para a preparaÇço de um medicamento para a prevenÇço ou tratamento de distérbios distÍmicos ou do sono
JP2010504957A (ja) 2006-09-29 2010-02-18 アクテリオン ファーマシューティカルズ リミテッド 3−アザ−ビシクロ[3.1.0]ヘキサン誘導体
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
AR064561A1 (es) 2006-12-28 2009-04-08 Actelion Pharmaceuticals Ltd Derivados de 2-aza-biciclo[3.1.0]hexano y su uso en la preparacion de un medicamento para el tratamiento de enfermedades relacionadas con disfunciones generales del sistema de la orexina.
WO2008087611A2 (en) 2007-01-19 2008-07-24 Actelion Pharmaceuticals Ltd Pyrrolidine- and piperidine- bis-amide derivatives
CL2008000836A1 (es) 2007-03-26 2008-11-07 Actelion Pharmaceuticals Ltd Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras.
EP2155739B1 (en) 2007-05-14 2010-10-06 Actelion Pharmaceuticals Ltd. 2-cyclopropyl-thiazole derivatives
EP2150115B1 (en) 2007-05-23 2013-09-18 Merck Sharp & Dohme Corp. Cyclopropyl pyrrolidine orexin receptor antagonists
BRPI0812981A2 (pt) 2007-07-03 2014-12-16 Glaxo Group Ltd Derivados de piperidina úteis como antagonistas dos receptores de orexina
CA2691373A1 (en) 2007-07-03 2009-01-08 Actelion Pharmaceuticals Ltd 3-aza-bicyclo[3.3.0]octane compounds
GB0712888D0 (en) 2007-07-03 2007-08-15 Glaxo Group Ltd Novel compounds
EP2183246A2 (en) 2007-07-27 2010-05-12 Actelion Pharmaceuticals Ltd. 2-aza-bicyclo-[3.3.0]-octane derivatives
WO2009016560A2 (en) 2007-07-27 2009-02-05 Actelion Pharmaceuticals Ltd Trans-3-aza-bicyclo[3.1.0]hexane derivatives
US8288411B2 (en) 2007-09-24 2012-10-16 Actelion Pharmaceuticals Ltd. Pyrrolidines and piperidines as orexin receptor antagonists
PE20091010A1 (es) 2007-10-10 2009-08-08 Actelion Pharmaceuticals Ltd Derivados de tetrahidroquinolina
ATE555107T1 (de) 2008-02-21 2012-05-15 Actelion Pharmaceuticals Ltd 2-aza-bicyclo-ä2,2,1-üheptan-derivate
GB0806536D0 (en) 2008-04-10 2008-05-14 Glaxo Group Ltd Novel compounds
US20110105491A1 (en) 2008-07-07 2011-05-05 Hamed Aissaoui Thiazolidine compounds as orexin receptor antagonists
WO2010038200A1 (en) 2008-10-01 2010-04-08 Actelion Pharmaceuticals Ltd Oxazolidine compounds as orexin receptor antagonists
EP2358713A1 (en) 2008-11-26 2011-08-24 Glaxo Group Limited Imidazopyridazine derivatives acting as orexin antagonists
JP2012509910A (ja) 2008-11-26 2012-04-26 グラクソ グループ リミテッド 新規の化合物
WO2010060471A1 (en) 2008-11-26 2010-06-03 Glaxo Group Limited Piperidine derivatives useful as orexin receptor antagonists
WO2010063663A1 (en) 2008-12-02 2010-06-10 Glaxo Group Limited N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0]hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof
CA2745420A1 (en) 2008-12-02 2010-06-10 Glaxo Group Limited N-{[(ir,4s,6r-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0] hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof
GB0823467D0 (en) * 2008-12-23 2009-01-28 Glaxo Group Ltd Novel Compounds
JP2012524760A (ja) 2009-04-24 2012-10-18 グラクソ グループ リミテッド オレキシンアンタゴニストとして使用される3−アザビシクロ[4.1.0]ヘプタン
US8895606B2 (en) 2010-08-24 2014-11-25 Actelion Pharmaceuticals Ltd. Proline sulfonamide derivatives as orexin receptor antagonists
US9242970B2 (en) 2010-11-10 2016-01-26 Actelion Pharmaceuticals Ltd. Lactam derivatives useful as orexin receptor antagonists
CN103380130B (zh) 2011-02-18 2015-06-17 埃科特莱茵药品有限公司 用作为食欲素拮抗剂的新颖的吡唑和咪唑衍生物
US9150566B2 (en) 2011-11-08 2015-10-06 Actelion Pharmaceuticals Ltd. 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-YL)picolinamide derivatives as orexin receptor antagonists
EA029899B1 (ru) 2012-06-04 2018-05-31 Идорсиа Фармасьютиклз Лтд Производные бензимидазол-пролина
WO2014057435A1 (en) 2012-10-10 2014-04-17 Actelion Pharmaceuticals Ltd Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives
CA2902135A1 (en) 2013-03-12 2014-09-18 Actelion Pharmaceuticals Ltd Azetidine amide derivatives as orexin receptor antagonists
UA119151C2 (uk) * 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
DK3077391T3 (en) 2013-12-04 2018-10-22 Idorsia Pharmaceuticals Ltd USE OF BENZIMIDAZOLE PROLINE DERIVATIVES

Also Published As

Publication number Publication date
HK1225731B (zh) 2017-09-15
SI3077389T1 (en) 2018-01-31
CL2016001342A1 (es) 2016-11-18
EP3077389B1 (en) 2017-09-13
SA516371231B1 (ar) 2018-02-20
US20160368901A1 (en) 2016-12-22
KR20160092015A (ko) 2016-08-03
MA39163B1 (fr) 2018-09-28
PH12016500988A1 (en) 2016-06-20
TW201605838A (zh) 2016-02-16
AU2014358742A1 (en) 2016-07-07
TWI664177B (zh) 2019-07-01
MY179862A (en) 2020-11-18
HRP20171773T1 (hr) 2017-12-29
UA119549C2 (uk) 2019-07-10
KR102361418B1 (ko) 2022-02-09
US9914720B2 (en) 2018-03-13
CA2929423A1 (en) 2015-06-11
AU2014358742B2 (en) 2019-02-07
EP3077389A1 (en) 2016-10-12
ES2651475T3 (es) 2018-01-26
PH12016500988B1 (en) 2016-06-20
PT3077389T (pt) 2017-12-15
IL245923A0 (en) 2016-08-02
NO3077389T3 (pl) 2018-02-10
MX2016007215A (es) 2016-09-07
CA2929423C (en) 2021-12-07
LT3077389T (lt) 2017-12-11
EA030137B1 (ru) 2018-06-29
NZ721438A (en) 2021-12-24
DK3077389T3 (da) 2017-11-13
IL245923B (en) 2019-09-26
WO2015083070A1 (en) 2015-06-11
MA39163A1 (fr) 2017-11-30
JP6496733B2 (ja) 2019-04-03
CN105793257A (zh) 2016-07-20
ZA201604499B (en) 2019-04-24
BR112016012628A2 (pl) 2017-08-22
MX364208B (es) 2019-04-16
BR112016012628A8 (pt) 2017-12-26
CY1119695T1 (el) 2018-04-04
HUE035731T2 (hu) 2018-05-28
CN105793257B (zh) 2018-11-13
EA201600435A1 (ru) 2016-11-30
JP2016539136A (ja) 2016-12-15

Similar Documents

Publication Publication Date Title
HK1225731B (zh) (s)-(2-(6-氯-7-甲基-1h-苯並[d]咪唑-2-基)-2-甲基吡咯啶-1-基)(5-甲氧基-2-(2h-1,2,3-三唑-2-基)苯基)甲酮的晶形及其作為食欲素受體拮抗劑的用途
HK1225736B (zh) (s)-(2-(6-氯-7-甲基-1h-苯並[d]咪唑-2-基)-2-甲基吡咯烷-1-基)(5-甲氧基-2-(2h-1,2,3-三唑-2-基)苯基)甲酮作為食欲素受體拮抗劑的結晶鹽形式
EP2694060A4 (en) SUBSTITUTED 3- (1H-BENZO [D] IMIDAZOL-2-YL) -1H-INDAZOLE ANALOGUES AS INHIBITORS OF PDK1 KINASE
HK1199022A1 (zh) -三唑- -基 苯甲酰胺及 -三唑- -基 吡啶酰胺衍生物
ME02606B (me) Jedinjenja 1,3 - oksazolidina ili 1,3- oksazinana kao antagonisti oreksinskog receptora
SMT201600012B (it) Composti eterociclici come leganti del recettore h3 dell'istamina
GB201321089D0 (en) Leukotriene receptor antagonists and their derivatives for use as antibacterial agents
EP2846800A4 (en) HETEROCYCLIC CGRP RECEPTOR ANTAGONISTS
TH1601000390A (th) เกลือของอนุพันธ์ 2-อะมิโน-1-ไฮดรอกซีเอทริล-8-ไฮดรอกซีควิโนลิน-2-(1H)-โอน(2-amino-1-hydroxyethyl-8-hydroxyquinolin-2(1H)-one) ซึ่งมีทั้งฤทธิ์มัสคารินิก รีเซพเตอร์แอนทาโกนิสและฤทธิ์ (เบต้า)2 อะดรีเนอร์จิกรีเซพเตอร์อะโกนิสต์